Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Danaher (NYSE:DHR) posted its quarterly earnings results on Tuesday. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20, Briefing.com reports. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period last year, the firm earned $2.36 EPS.

Danaher Price Performance

Danaher stock traded down $3.36 during mid-day trading on Wednesday, hitting $249.75. 1,103,403 shares of the company were exchanged, compared to its average volume of 2,755,977. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The business’s 50 day simple moving average is $248.95 and its two-hundred day simple moving average is $230.64. The company has a market capitalization of $184.95 billion, a P/E ratio of 39.08, a PEG ratio of 3.96 and a beta of 0.83. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Wall Street Analyst Weigh In

Several research firms have recently commented on DHR. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Royal Bank of Canada raised their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Citigroup raised their price objective on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Barclays raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $268.67.

Insiders Place Their Bets

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,957 shares of company stock valued at $8,265,802. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.